REVIEW ARTICLE Sue Rimes, et al; ONCOLOGY Nurse Edition Vol. 25 No. 10 Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
REVIEW ARTICLE John O. Schorge, et al; ONCOLOGY Vol. 25 No. 10 The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
NEWS & ANALYSIS Anna Azvolinsky, PhD Many doctors do not properly adhere to current guidelines for offering breast and ovarian cancer counseling and testing services to their female patients, according to a recent study from the Division of Cancer Prevention and Control at the CDC. The vignette-based national survey finds that while genetic counseling is recommended for women at high risk for breast and/or ovarian cancer, only 41% of physicians self-reported adhering to recommendations to refer for genetic counseling or testing.
REVIEW ARTICLE Maria Jose Echarri Gonzalez, et al;ONCOLOGY Vol. 25 No. 2 This article reviews the known data on the dose-effect relationship for platinum drugs in ovarian cancer, and explores why interest in platinum drugs has become the central focus of ovarian cancer treatment.
CME Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers. •The Complexity of Hereditary Cancer Syndromes
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
A 58-year-old woman with recurrent/metastatic ovarian cancer involving bones, inguinal lymph nodes, and soft tissue of the back develops tender swelling and mild to moderate erythema of both legs two days after her first infusion of gemcitabine (Gemzar).
We speak with two experts to discuss breast cancer risk, genetics, and prevention options available to women at high risk of developing breast and ovarian cancer. More »
Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic variations could help clinicians single out higher-risk men for screening and early detection. More »
Carcinoma of an unknown primary site is a common clinical syndrome, accounting for approximately 3% of all oncologic diagnoses. Patients in this group are heterogeneous, having a wide variety of clinical presentations and pathologic findings. More »
I looked after one of my partner’s patients who is approaching death from advanced, refractory ovarian cancer. She asked me not to talk about anything negative with her. We can’t really make any decisions without discussing negative things. Should I just remain silent about them at her request? More »
Ongoing studies are attempting to understand the reasons that tumor cells engage in aerobic glycolysis in lieu of oxidative phosphorylation. In this review, we discuss known benefits to tumor cells from this metabolic switch, and we highlight key enzymes that play a role in aerobic glycolysis. We also describe novel therapeutic options targeting glucose metabolism. More »
CancerNetwork interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.
The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
Epithelial ovarian cancer spreads prominently within the peritoneal cavity. In fact, we now know that high-grade serous cancers are often of tubal origin, and their presentation as tubo-ovarian masses renders it likely that IP spread occurs as an early event in their clinical evolution.
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
A 58-year-old woman with recurrent/metastatic ovarian cancer involving bones, inguinal lymph nodes, and soft tissue of the back develops tender swelling and mild to moderate erythema of both legs two days after her first infusion of gemcitabine (Gemzar).
CancerNetwork interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
